KR20240093575A - Hdac 조절제에 의한 당뇨병 및 합병증의 치료 방법 또는 치료제 - Google Patents

Hdac 조절제에 의한 당뇨병 및 합병증의 치료 방법 또는 치료제 Download PDF

Info

Publication number
KR20240093575A
KR20240093575A KR1020247015966A KR20247015966A KR20240093575A KR 20240093575 A KR20240093575 A KR 20240093575A KR 1020247015966 A KR1020247015966 A KR 1020247015966A KR 20247015966 A KR20247015966 A KR 20247015966A KR 20240093575 A KR20240093575 A KR 20240093575A
Authority
KR
South Korea
Prior art keywords
diabetes
blood sugar
cells
treatment
hdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015966A
Other languages
English (en)
Korean (ko)
Inventor
히데토 코지마
미와코 카타기
Original Assignee
가부시키가이샤 바이오지프코드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 바이오지프코드 filed Critical 가부시키가이샤 바이오지프코드
Publication of KR20240093575A publication Critical patent/KR20240093575A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247015966A 2021-10-29 2022-10-27 Hdac 조절제에 의한 당뇨병 및 합병증의 치료 방법 또는 치료제 Pending KR20240093575A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-177845 2021-10-29
JP2021177845 2021-10-29
PCT/JP2022/040140 WO2023074794A1 (ja) 2021-10-29 2022-10-27 Ｈｄａｃ調節剤による糖尿病ならびに合併症の治療方法または治療剤

Publications (1)

Publication Number Publication Date
KR20240093575A true KR20240093575A (ko) 2024-06-24

Family

ID=86159956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015966A Pending KR20240093575A (ko) 2021-10-29 2022-10-27 Hdac 조절제에 의한 당뇨병 및 합병증의 치료 방법 또는 치료제

Country Status (7)

Country Link
EP (1) EP4424327A4 (https=)
JP (1) JPWO2023074794A1 (https=)
KR (1) KR20240093575A (https=)
CN (1) CN118475370A (https=)
AU (1) AU2022376087A1 (https=)
IL (1) IL312393A (https=)
WO (1) WO2023074794A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114828890A (zh) * 2019-10-18 2022-07-29 比奥兹普科德公司 使用了干细胞迁移剂的糖尿病治疗
JP2021177845A (ja) 2020-05-12 2021-11-18 株式会社サンセイアールアンドディ 遊技機
KR20230152099A (ko) * 2021-02-26 2023-11-02 가부시키가이샤 바이오지프코드 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
당뇨병 진료 가이드 라인 2016, 일본 당뇨병 학회, 난코도

Also Published As

Publication number Publication date
JPWO2023074794A1 (https=) 2023-05-04
EP4424327A4 (en) 2025-12-31
WO2023074794A1 (ja) 2023-05-04
IL312393A (en) 2024-06-01
EP4424327A1 (en) 2024-09-04
CN118475370A (zh) 2024-08-09
AU2022376087A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
Whittam et al. Small molecule inhibition of dipeptidyl peptidase-4 enhances bone marrow progenitor cell function and angiogenesis in diabetic wounds
Quinteiro et al. The indirect antinociceptive mechanism of 15 d‐PGJ 2 on rheumatoid arthritis‐induced TMJ inflammatory pain in rats
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
US20230263817A1 (en) High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
KR20240093575A (ko) Hdac 조절제에 의한 당뇨병 및 합병증의 치료 방법 또는 치료제
US20220088010A1 (en) Co-Administration of inhibitors to produce insulin producing gut cells
KR20140054369A (ko) 당뇨병 치료를 위한 ｍｇ２９를 조정하는 조성물 및 방법
US10330670B2 (en) Therapeutic or prophylactic agent for retinopathy of prematurity, testing method for retinopathy of prematurity, and screening method for therapeutic or prophylactic substance for retinopathy of prematurity
WO2021075535A1 (ja) 異常幹細胞を標的とする糖尿病治療
Bauer The Impact of Mig6 on Pancreatic Endocrine Cell Fate: Alpha and Beta Cell Mass in Health and Disease
HK40105070A (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
Seelam GLP1R IS AT CELL NEGATIVE COSTIMULATORY MOLECULE
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
HK40073547A (en) Therapy for diabetes using stem cell migration agent
HK40074315A (en) Therapy for diabetes using stem cell migration agent
HK40073790A (en) Diabetes therapy targeting abnormal stem cells
Dickenson et al. Pharmacology: Paper alert
Olaniru The Role of GPR56 and Collagen III in Islet Functions
Keystone 3rd Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences Translation of Basic Insights Into Clinical Practice
Kass Modulation of the β-Adrenergic Stimulated Inotropy by PDE5a Inhibition Is Blunted and Redox-Sensitive in Myocytes from Chronically Hypertrophied or Failing Heart: P22
Yang Peroxisome Proliferator-Activated Receptor γ Is Essential to Maintain Myocardial Redox Homeostasis: P33
Azuma Impaired Mitochondrial Ultrastructure and Metabolic Function in Cardiac and Skeletal Muscle in Taurine-Deficient Mice: P34

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000